The Journal of Urology
Volume 182, Issue 6, Supplement , Pages S38-S44 , December 2009

Impact of Diabetes and Obesity on the Prostate and Urethra: Implications to Improved Bladder Dysfunction Understanding and Treatment

  • George J. Christ

      Affiliations

    • Wake Forest Institute for Regenerative Medicine, Wake Forest University Health Sciences, Winston-Salem, North Carolina
    • Corresponding Author InformationCorrespondence: Cell, Tissue and Organ Physiology Program, Wake Forest Institute for Regenerative Medicine, Wake Forest University Baptist Medical Center, Dean Research Building, Room 442, Medical Center Blvd., Winston-Salem, North Carolina 27157 (telephone: 336-713-7296; FAX: 336-713-7290)
    • ,
  • Wade Bushman

      Affiliations

    • Department of Urology, University of Wisconsin Medical School Madison, Madison, Wisconsin
    • ,
  • Matthew O. Fraser

      Affiliations

    • Division of Urology, Department of Surgery, Duke University Medical Center and Durham Veterans Administration Medical Center, Durham, North Carolina

References 

  1. Kaplan SA, Roehrborn CG, Chapple CR, et al. Implications of recent epidemiology studies for the clinical management of lower urinary tract symptoms. BJU Int. 2009;103(suppl.):48
  2. McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int. 2006;97(suppl.):23
  3. Sarma AV, Kanaya A, Nyberg LM, et al. Risk factors for urinary incontinence among women with type 1 diabetes: findings from the Epidemiology of Diabetes Interventions and Complications Study. Urology. 2009;73:1203
  4. Sarma AV, Kanaya AM, Nyberg LM, et al. Urinary incontinence among women with type 1 diabetes: how common is it?. J Urol. 2009;181:1224
  5. Steers WD. Food for thought: obesity as the major contributing factor for most urological disorders. J Urol. 2009;181:1983
  6. Yoshimura N, Chancellor MB, Andersson KE, et al. Recent advances in understanding the biology of diabetes-associated bladder complications and novel therapy. BJU Int. 2005;95:733
  7. Chapple CR, Wein AJ, Abrams P, et al. Lower urinary tract symptoms revisited: a broader clinical perspective. Eur Urol. 2008;54:563
  8. Coyne KS, Kaplan SA, Chapple CR, et al. Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS. BJU Int. 2009;103(suppl.):24
  9. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306
  10. McVary KT. BPH: epidemiology and comorbidities. Am J Manag Care. 2006;12:S122
  11. Sexton CC, Coyne KS, Kopp ZS, et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int. 2009;103(suppl.):12
  12. Parsons JK, Carter HB, Partin AW, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006;91:2562
  13. Hammarsten J, Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press. 1999;8:29
  14. Rohrmann S, Smit E, Giovannucci E, et al. Associations of obesity with lower urinary tract symptoms and noncancer prostate surgery in the Third National Health and Nutrition Examination Survey. Am J Epidemiol. 2004;159:390
  15. Boon TA, Van Venrooij GE, Eckhardt MD. Effect of diabetes mellitus on lower urinary tract symptoms and dysfunction in patients with benign prostatic hyperplasia. Curr Urol Rep. 2001;2:297
  16. Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol. 2001;39:151
  17. Michel MC, Mehlburger L, Schumacher H, et al. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol. 2000;163:1725
  18. Hunskaar S. A systematic review of overweight and obesity as risk factors and targets for clinical intervention for urinary incontinence in women. Neurourol Urodyn. 2008;27:749
  19. Brown JS. Diabetic cystopathy: what does it mean?. J Urol. 2009;181:13
  20. Zotova EG, Christ GJ, Zhao W, et al. Effects of fidarestat, an aldose reductase inhibitor, on nerve conduction velocity and bladder function in streptozotocin-treated female rats. J Diabetes Complications. 2007;21:187
  21. Brading AF. The physiology of the mammalian urinary outflow tract. Exp Physiol. 1999;84:215
  22. Brading AF, Teramoto N, Dass N, et al. Morphological and physiological characteristics of urethral circular and longitudinal smooth muscle. Scand J Urol Nephrol. 2001;35(suppl.):12
  23. de Groat WC, Fraser MO, Yoshiyama M, et al. Neural control of the urethra. Scand J Urol Nephrol. 2001;35(suppl.):35
  24. Mamas MA, Reynard JM, Brading AF. Nitric oxide and the lower urinary tract: current concepts, future prospects. Urology. 2003;61:1079
  25. Abdel-Hakim A, Hassouna M, Rioux F, et al. Response of urethral smooth muscles to pharmacological agents (II. Noncholinergic, nonadrenergic agonists and antagonists). J Urol. 1983;130:988
  26. Persson CG, Andersson KE. Adrenoceptor and cholinoceptor mediated effects in the isolated urethra of cat and guinea-pig. Clin Exp Pharmacol Physiol. 1976;3:415
  27. Bennett BC, Kruse MN, Roppolo JR, et al. Neural control of urethral outlet activity in vivo: role of nitric oxide. J Urol. 1995;153:2004
  28. Yoshiyama M, deGroat WC, Fraser MO. Influences of external urethral sphincter relaxation induced by alpha-bungarotoxin, a neuromuscular junction blocking agent, on voiding dysfunction in the rat with spinal cord injury. Urology. 2000;55:956
  29. Brading AF, McCoy R, Dass N. Alpha1-adrenoceptors in urethral function. Eur Urol. 1999;36(suppl.):74
  30. Jung SY, Fraser MO, Ozawa H, et al. Urethral afferent nerve activity affects the micturition reflex; implication for the relationship between stress incontinence and detrusor instability. J Urol. 1999;162:204
  31. Yang Z, Nassar R, Dolber PC, et al. Voltage-dependent potassium currents of urethral afferent neurons in diabetes mellitus. Brain Res. 2008;1217:132
  32. Liu G, Lin YH, Yamada Y, et al. External urethral sphincter activity in diabetic rats. Neurourol Urodyn. 2008;27:429
  33. Torimoto K, Fraser MO, Hirao Y, et al. Urethral dysfunction in diabetic rats. J Urol. 2004;171:1959
  34. Torimoto K, Hirao Y, Matsuyoshi H, et al. Alpha1-adrenergic mechanism in diabetic urethral dysfunction in rats. J Urol. 2005;173:1027
  35. Yang Z, Dolber PC, Fraser MO. Diabetic urethropathy compounds the effects of diabetic cystopathy. J Urol. 2007;178:2213
  36. Mitsui T, Kakizaki H, Kobayashi S, et al. Vesicourethral function in diabetic patients: association of abnormal nerve conduction velocity with vesicourethral dysfunction. Neurourol Urodyn. 1999;18:639
  37. Moon JH, Kang SW, Chun SI. Pudendal somatosensory evoked potential and bulbocavernosus reflex testing in erectile dysfunction. Yonsei Med J. 1993;34:71
  38. Sarica Y, Karatas M, Bozdemir H, et al. Cerebral responses elicited by stimulation of the vesico-urethral junction (VUJ) in diabetics. Electroencephalogr Clin Neurophysiol. 1996;100:55
  39. Prantil RL, Jankowski RJ, Torimoto K, et al. Dramatic effects of diabetes mellitus on urethral biomechanics: implications for diabetic cystopathy. J Urol. 2002;167:248
  40. Chang LS, Yang Z, Nassar R, et al. The effects of type I Diabetes mellitus on urethral smooth muscle in the female rat: in vitro strip studies. In: November 15–19, 2008;Presented at annual meeting of Society for Neuroscience, Washington, D.C., program 84.5
  41. Sasaki K, Yoshimura N, Chancellor MB. Implications of diabetes mellitus in urology. Urol Clin North Am. 2003;30:1
  42. Andersson KE, Uckert S, Stief C, et al. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. Neurourol Urodyn. 2007;26:928
  43. Andersson KE, Gratzke C. Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol. 2007;4:368
  44. Michel MC, Barendrecht MM. Physiological and pathological regulation of the autonomic control of urinary bladder contractility. Pharmacol Ther. 2008;117:297

 Financial interest and/or other relationship with Ion Channel Innovations and Terigion.

PII: S0022-5347(09)01833-3

doi: 10.1016/j.juro.2009.07.085

The Journal of Urology
Volume 182, Issue 6, Supplement , Pages S38-S44 , December 2009

Article Tools

* Image Usage & Resolution